Etelcalcetide shows promise for reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Nancy E. Lane, MD, professor of medicine, at the University of California at Davis School of Medicine, discusses results from the phase 3 ACTIVE trial.
Study reveals 6-fold higher risk of secondary hyperparathyroidism in patients on furosemide vs hydrochlorothiazide.
The therapy was also associated with reduced urinary calcium excretion and stable serum calcium concentration in patients with hypoparathyroidism.
Quality-of-life scores improved significantly after successful parathyroidectomy.
Reduced fracture risk for surgery; bisphosphonate treatment no better than observation
Recent data showed that parathyroidectomy is more effective for controlling hypercalcemia after kidney transplants in patients with persistent hyperparathyroidism.
The correlation persists regardless of concurrent oral bisphosphonate administration.
PTH (1-84) for 7 years is linked to reduced calcium and calcitriol supplementation.
Hemodialysis patients who undergo the procedure experience decreased risks of all-cause and cardiovascular mortality.
Cyclic treatment with teriparatide yields improvements in bone mineral density that are similar to daily treatment in women taking alendronate.
Shire announced the launch of Natpara (parathyroid hormone) for injection indicated as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism
The FDA has approved Natpara (parathyroid hormone) to control hypocalcemia in patients with hypoparathyroidism.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted to recommend approval of recombinant human parathyroid hormone for hypoparathyroidism.
Elevated parathyroid hormone levels may play a role in the development of vascular dementia.
More patients with abnormal bone mineral density should undergo screening for primary hyperparathyroidism.
Patients with hypoparathyroidism may benefit from treatment with recombinant human parathyroid hormone.
AMG 416 demonstrated positive results for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Risk for heart failure appeared to be increased with elevated parathyroid hormone levels.
Levels of parathyroid hormone (PTH) should be considered when evaluating the effect of vitamin D status on glucose metabolism.
Endocrinology Advisor Articles
- Effect of Sugar-Sweetened Beverages on Obesity Development
- Metformin and PCOS: Improving Menstrual Cycle and Hormone Profiles
- Denosumab May Increase BMD in Women With Primary Hyperparathyroidism
- T2D May Play a Protective Role Against Developing Aortic Diseases
- Risk Factors for Diabetes May Be Identified 20 Years Before Diagnosis
- Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease
- SGLT2 Inhibitors Show High Cardiovascular- and Renal-Protective Effects in T2D
- Type 2 Diabetes Insulin Initiation: Predictors Identified
- Two New Diabetes Medications Now Available
- Managing Acute Pain in Patients With Severe Obesity
- Risk for Congenital Malformations With Antithyroid Drugs
- Occupational Therapy May Benefit Young Adults With Diabetes
- Weight Loss May Improve Pain in Patients With Obesity
- Prior Authorizations Are Creating a Challenge for Clinicians
- Effect of Biologic DMARDs on Spinal Fracture Risk in Ankylosing Spondylitis